Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma

Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet